114 related articles for article (PubMed ID: 16428027)
1. Assessment of the antibacterial activity of galangin against 4-quinolone resistant strains of Staphylococcus aureus.
Cushnie TP; Lamb AJ
Phytomedicine; 2006 Feb; 13(3):187-91. PubMed ID: 16428027
[TBL] [Abstract][Full Text] [Related]
2. Reversing β-lactam antibiotic resistance of Staphylococcus aureus with galangin from Alpinia officinarum Hance and synergism with ceftazidime.
Eumkeb G; Sakdarat S; Siriwong S
Phytomedicine; 2010 Dec; 18(1):40-5. PubMed ID: 21036573
[TBL] [Abstract][Full Text] [Related]
3. Aggregation of Staphylococcus aureus following treatment with the antibacterial flavonol galangin.
Cushnie TP; Hamilton VE; Chapman DG; Taylor PW; Lamb AJ
J Appl Microbiol; 2007 Nov; 103(5):1562-7. PubMed ID: 17953567
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the antibacterial activity of selected flavonoids and consideration of discrepancies between previous reports.
Cushnie TP; Hamilton VE; Lamb AJ
Microbiol Res; 2003; 158(4):281-9. PubMed ID: 14717448
[TBL] [Abstract][Full Text] [Related]
5. Detection of galangin-induced cytoplasmic membrane damage in Staphylococcus aureus by measuring potassium loss.
Cushnie TP; Lamb AJ
J Ethnopharmacol; 2005 Oct; 101(1-3):243-8. PubMed ID: 15985350
[TBL] [Abstract][Full Text] [Related]
6. Extended spectrum of quinolone resistance, even to a potential latter third-generation agent, as a result of a minimum of two GrlA and two GyrA alterations in quinolone-resistant Staphylococcus aureus.
Yoon EJ; Lee CY; Shim MJ; Min YH; Kwon AR; Lee J; Choi EC
Chemotherapy; 2010; 56(2):153-7. PubMed ID: 20407243
[TBL] [Abstract][Full Text] [Related]
7. Increased antibacterial activity of DW286, a novel fluoronaphthyridone antibiotic, against Staphylococcus aureus strains with defined mutations in DNA gyrase and topoisomerase IV.
Yun HJ; Min YH; Jo YW; Shim MJ; Choi EC
Int J Antimicrob Agents; 2005 Apr; 25(4):334-7. PubMed ID: 15784314
[TBL] [Abstract][Full Text] [Related]
8. Galangin expresses bactericidal activity against multiple-resistant bacteria: MRSA, Enterococcus spp. and Pseudomonas aeruginosa.
Pepeljnjak S; Kosalec I
FEMS Microbiol Lett; 2004 Nov; 240(1):111-6. PubMed ID: 15500987
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of the new quinolone WCK 771 against staphylococci.
Jacobs MR; Bajaksouzian S; Windau A; Appelbaum PC; Patel MV; Gupte SV; Bhagwat SS; De Souza NJ; Khorakiwala HF
Antimicrob Agents Chemother; 2004 Sep; 48(9):3338-42. PubMed ID: 15328094
[TBL] [Abstract][Full Text] [Related]
10. Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition.
Takei M; Fukuda H; Kishii R; Hosaka M
Antimicrob Agents Chemother; 2001 Dec; 45(12):3544-7. PubMed ID: 11709337
[TBL] [Abstract][Full Text] [Related]
11. Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae.
Okumura R; Hirata T; Onodera Y; Hoshino K; Otani T; Yamamoto T
J Antimicrob Chemother; 2008 Jul; 62(1):98-104. PubMed ID: 18390884
[TBL] [Abstract][Full Text] [Related]
12. Apigenin as an anti-quinolone-resistance antibiotic.
Morimoto Y; Baba T; Sasaki T; Hiramatsu K
Int J Antimicrob Agents; 2015 Dec; 46(6):666-73. PubMed ID: 26526895
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.
Chen YH; Liu CY; Lu JJ; King CH; Hsueh PR
J Antimicrob Chemother; 2009 Dec; 64(6):1226-9. PubMed ID: 19833635
[TBL] [Abstract][Full Text] [Related]
14. Effect of certain bioactive plant extracts on clinical isolates of beta-lactamase producing methicillin resistant Staphylococcus aureus.
Aqil F; Khan MS; Owais M; Ahmad I
J Basic Microbiol; 2005; 45(2):106-14. PubMed ID: 15812867
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010).
Farrell DJ; Castanheira M; Mendes RE; Sader HS; Jones RN
Clin Infect Dis; 2012 Sep; 55 Suppl 3():S206-14. PubMed ID: 22903953
[TBL] [Abstract][Full Text] [Related]
16. Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models.
Patel MV; De Souza NJ; Gupte SV; Jafri MA; Bhagwat SS; Chugh Y; Khorakiwala HF; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 2004 Dec; 48(12):4754-61. PubMed ID: 15561853
[TBL] [Abstract][Full Text] [Related]
17. Antibacterial and antimycobacterial lignans and flavonoids from Larrea tridentata.
Favela-Hernández JM; García A; Garza-González E; Rivas-Galindo VM; Camacho-Corona MR
Phytother Res; 2012 Dec; 26(12):1957-60. PubMed ID: 22422605
[TBL] [Abstract][Full Text] [Related]
18. Modulation of drug resistance in Staphylococcus aureus by a kaempferol glycoside from Herissantia tiubae (Malvaceae).
Falcão-Silva VS; Silva DA; Souza Mde F; Siqueira-Junior JP
Phytother Res; 2009 Oct; 23(10):1367-70. PubMed ID: 19224523
[TBL] [Abstract][Full Text] [Related]
19. [In vitro activity of new quinolones against clinical strains of Staphylococcus aureus of the wild type and with mutations characterized by gyrA, gyrB and grlA].
Yagüe Guirao G; Martínez-Toldos MC; Alonso Manzanares MA; Gutiérrez Zufiaurre MN; Martínez-Andrés JA; Muñoz Bellido JL; García-Rodríguez JA; Segovia Hernández M
Rev Esp Quimioter; 2000 Sep; 13(3):271-5. PubMed ID: 11086276
[TBL] [Abstract][Full Text] [Related]
20. Susceptibilities of healthcare- and community-associated methicillin-resistant staphylococci to the novel des-F(6)-quinolone DX-619.
Watanabe S; Ito T; Hiramatsu K
J Antimicrob Chemother; 2007 Dec; 60(6):1384-7. PubMed ID: 17890283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
